AstraZeneca (NASDAQ: AZN)’s Chinese subsidiary has announced a strategic restructuring of its China biopharmaceutical business unit (BBU), with Lin Xiao, currently the general manager of AstraZeneca China’s biopharmaceutical operations and head of the Hong Kong and Macau Region, being appointed to lead the division.
The restructuring entails the integration of the omni channel division into the BBU, with the leaders of the omni channel, county, retail, community, and Feiying business units now directly reporting to Lin Xiao. In a consolidation of efforts, the respiratory inhalation business, respiratory nebulization business, and digestion business have been merged to form a new respiratory digestion division. Liu Qian, the current general manager of AstraZeneca China’s omnichannel business unit, will take full responsibility for this new division and report to Lin Xiao. Additionally, the biopharmaceutical business, vaccine and immunotherapy, and autoimmune business departments have been consolidated into a respiratory and autoimmune biopharmaceutical, vaccine, and immunotherapy business department, led by Chen Xi, who will also report to Lin Xiao.
AstraZeneca China’s business is primarily segmented into biopharmaceuticals, oncology, and rare diseases. The biopharmaceuticals segment now encompasses the respiratory and digestive division, the newly formed respiratory and autoimmune biopharmaceutical, vaccine and immunotherapy division, as well as the cardiovascular, renal, and metabolic division, along with the omnichannel and county, retail, community, and Feiying business teams.
This strategic move aims to enhance collaboration in chronic disease management both within and outside of hospitals and to broaden the reach of respiratory disease treatments in smaller towns and grassroots markets.- Flcube.com
